Hematologic Malignancies

Hematologic Malignancies

Transfusion Therapy for Hematological Malignancies Post-Anticancer Treatment

Differences between hematologists and palliative care physicians when it comes indicating the need for transfusion therapy among patients with end-stage hematological malignancies are highlighted. 

Oncology Times - Latest Articles
A Novel Germline Heterozygous BCL11B Variant Causing Severe Atopic Disease and Immune Dysregulation

Researchers work to classify germline BCL11B-dependent atopic disease as a novel primary atopic disorder.

Frontiers in Immunology
Metagenomic Analysis to Identify Novel Infectious Agents in Systemic Anaplastic Large Cell Lymphoma

A metagenomic analysis of systemic ALCL was conducted to determine whether a known or novel pathogen is associated with this malignancy. 

Infectious Agents and Cancer

Updated NCCN Guidelines Now Include Zanubrutinib for WM

The updated guidelines for management of WM from the NCCN now include the second-generation product zanubrutinib, which was approved for the treatment of this disease just a month ago.

Precision Medicine Approach Leads to ‘Exceptional Responses’ in Patients With Aggressive Hematologic Cancers

In the EXALT trial, researchers used an image-based single-cell functional precision medicine approach to guide treatment of patients with aggressive hematologic cancers.

Cancer Therapy Advisor
Study Finds Younger B-Cell Non-Hodgkin Lymphoma Survivors May Have a Higher Risk of Age-Related Diseases Than Older Survivors

B-NHL survivors younger than age 65 had higher relative risks of developing acute renal failure, pneumonia, and nutritional deficiencies than older counterparts...

The ASCO Post
Factors Associated With Low Palliative Care Consultation in Hospitalized Patients at the End of Life

Among patients who were hospitalized at the end of life, early palliative care consultation was significantly lower for those with hematological malignancies than for those with other malignancies.

Hematology Advisor
Autologous HSCT Provides Long-Term Survival Benefit in Mantle Cell Lymphoma

Autologous HSCT provides a long-term survival benefit, when compared with IFN-alfa maintenance, in patients with advanced MCL, according to research published in The Lancet Haematology.

Hematology Advisor
Concurrent Ibrutinib Plus Venetoclax in Relapsed/Refractory Mantle Cell Lymphoma

The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administered, once-daily, all-oral ibrutinib plus venetoclax in patients with relapsed/refractory MCL.

Journal of Hematology & Oncology
Sintilimab for Relapsed/Refractory Extranodal NK/T Cell Lymphoma

ORIENT-4 aimed to assess the efficacy and safety of sintilimab, a humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell lymphoma. 

Signal Transduction & Targeted Therapy
Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-Risk B- and T-Cell Acute Lymphoblastic Leukemia

Researchers outline the benefits of developing NK cell profiling as a diagnostic tool to predict clinical outcome in patients with ALL and underscore the clinical potential of allogeneic NK cells..

How Artificial Intelligence Can Help Diagnose Leukemia

Researchers find AI provides the potential to fully utilize all measurement values and increases the speed as well as the objectivity of the analyses compared to established processes.

Oncology Times - Latest Articles
Comparison of Generic and Branded Imatinib for Patients With Chronic Myeloid Leukemia

A recent systematic review of 36 studies on the use of generic imatinib suggests that generic imatinib has performed similarly to branded imatinib regarding efficacy and safety in treatment of CML.

Hematology Advisor
Genomic Markers May Predict Clinical Outcomes in Patients With B-Cell Acute Lymphoblastic Leukemia

Among adult patients with BCRABL1 negative B-ALL, genomic evaluation may lead to improved risk assessment, according to research published in Blood.

Hematology Advisor
COVID-19 Infection in Adult Patients With Hematological Malignancies

Baseline characteristics of HM patients developing COVID-19 were studied and analyzed as predictors of mortality.

Journal of Hematology & Oncology
Researchers Identify New Drug Target for Blood Cancer, Potentially Solid Tumors

Mutations that produce an alternative version of the protein created by the gene GNAS that can be targeted by drugs already approved by the FDA for treating other cancers...

Science Daily
Mutant NPM1-Regulated lncRNA HOTAIRM1 Promotes Leukemia Cell Autophagy and Proliferation by Targeting EGR1 and ULK3

Scientists investigate the functional and mechanistic roles of the lncRNA HOTAIRM1 to improve the diagnosis and treatment of patients with NPM1-mutated AML.

Journal of Experimental & Clinical Cancer Research
Analysis of Cellular Heterogeneity in Immune Microenvironment of Primary Central Nervous System Lymphoma by Single-Cell Sequencing

Scientists performed an analysis of scRNA-seq data of CNS tissue sequenced by 10x Genomics to identify the cell types of CNS cells.

Frontiers in Oncology
Mutation Analysis Links Angioimmunoblastic T-cell Lymphoma to Clonal Hematopoiesis and Smoking

Researchers explore the initiation and progression of AITL and PTCL-NOS to find the subset of AITL/PTCL-NOS patients that develop CHN and find a biomarker to predict this risk. 

Safety of a Bispecific Antibody in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Researchers aimed to determine the safety and tolerability of APVO436 in patients with R/R AML or MDS and to identify a recommended phase 2 dose (RP2D) level.

Hematology Advisor
Detailed Characterization of the Transcriptome of Single B Cells in Mantle Cell Lymphoma Suggesting a Potential Use for SOX4

Researchered investigated the transcriptome of MCL cells from eight diagnostic BM samples to provide insight into the complex and diverse molecular architecture of MCL at the single-cell transcript

Scientific Reports
Single-Cell RNA Sequencing Reveals Markers of Disease Progression in Primary Cutaneous T-cell Lymphoma

Scientists profiled patches with longstanding history, and compared them with recently developed plaques or tumors within the same patient to overcome inter-individual variability. 

Molecular Cancer
Differential Effects of Donor Lymphocyte Infusion Upon Treatment Response and GVHD According to Relapse Level and Donor Sources in Patients With Myelodysplastic Syndrome

In this study, investigators analyzed 61 consecutive myelodysplastic syndrome and secondary AML patients receiving DLI for the control of post-SCT relapse.

Therapeutic Advances in Hematology
Hypomethylating Agents and FLT3 Inhibitors as Maintenance Treatment for AML and Myelodysplastic Syndrome Following Allogeneic Hematopoietic Stem Cell Transplant

This study aims to synthesize the current evidence on the efficacy and safety of FLT3 inhibitors and HMA for maintenance therapy following allo-HCT in AML and MDS.

Transplantation and Cellular Therapy
Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation

Researchers retrospectively compared SAA that had progressed from NSAA in patients undergoing first-line IST (n=229) with patients meeting the criteria for SAA at the time of diagnosis (n=232)...

Frontiers in Oncology
Bortezomib and Rituximab in de novo Adolescent/Adult CD20-Positive, Ph-Negative Pre-B-Cell Acute Lymphoblastic Leukemia

Scientists evaluate the activity of this combination during induction in adolescents and adults with CD20+ Ph– precursor B-ALL...

Blood Advances
Inhibiting DNA Repair in Hematologic Malignancies & Solid Tumors

Researchers evaluating the safety and efficacy of CYT-0851 find the first-in-class small molecule inhibitor of RAD51-mediated DNA repair is well-tolerated by patients and has promising anti-tumor..

Oncology Times - Latest Articles
The Safety of the COVID-19 Vaccine for Blood Cancer Patients

About one in four blood cancer patients fail to produce detectable antibodies after COVID-19 vaccination, but results vary substantially by type of blood cancer, according to a new study...

Oncology Times - Latest Articles
Mechanism of Leukemia Pathogenesis & Possible Targeted Therapy

In a new research paper, scientists describe how molecular mechanisms of the ASXL1 gene mutation are involved in leukemia pathogenesis, and they also identify a possible targeted therapy for...

Oncology Times - Latest Articles
Study Explores Relationship Between Anti-CD20 Therapy and Reduced Responses to mRNA COVID-19 Vaccines

Patients with lymphoma or other lymphoid cancers should continue to take steps to protect themselves from COVID-19 even if they have been vaccinated against the disease.

The ASCO Post
Benign and Malignant Hematologic Manifestations in Patients With VEXAS Syndrome Due to Somatic Mutations in UBA1

Patients with VEXAS syndrome have a propensity toward developing cytopenia, MDS, multiple myeloma, and venous thromboembolism.

Blood Advances
Second-Line CAR-T Fails to Extend EFS in Aggressive B-cell Non-Hodgkin Lymphoma

A randomized phase 3 trial that evaluated tisagenlecleucel as second-line treatment of relapsed or refractory aggressive B-cell NHL failed to meet its primary endpoint of improved EFS

CHIP May Affect Some Outcomes in Patients Receiving CAR T-Cell Therapy

Clonal hematopoiesis of indeterminate potential is associated with some outcomes of CAR T-cell therapy, according to research published in Blood Advances.

Cancer Therapy Advisor

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)